Concord Biotech, Vaibhav Gems Get Approval To Launch IPOs (Public Issue)
Rare Enterprises-backed Concord Biotech and regional jewellery brand Vaibhav Gems N' Jewellers have received capital markets regulator Sebi's go-ahead to raise funds through initial public offerings (IPOs).
The two companies filed their preliminary IPO papers with the capital markets regulator between August and September and obtained their observation letters during November 28-December 2, an update with the Securities and Exchange Board of India (Sebi) showed on Tuesday.
In Sebi's parlance, its observations imply its go-ahead to float initial share sales. According to the draft papers, Concord Biotech's IPO is entirely an offer for sale of (OFS) of 2,09,25,652 equity shares by Helix Investment Holdings Pte Limited, backed by private equity firm Quadria Capital.
Concord is among the leading manufacturers of fermentation-based biopharmaceutical APIs focused on niche segments, such as immunosuppressant, oncology, anti-fungal and anti-bacterial. It has three manufacturing facilities -- Valthera, Dholka, and Limbasi -- in Gujarat.
The company is backed by Quadria Capital Fund and Rare Enterprises, which was set up by billionaire investor Rakesh Jhunjhunwala, along with his wife Rekha. The veteran stock market investor passed away in August this year.
Ahmedabad-based biopharma firm held a portfolio of 56 brands and 65 products, including 22 APIs and 43 formulations as of March 2022. In addition, it has filed over 120 drug master files (DMFs) across several countries.
The public issue of Vaibhav Gems N' Jewellers comprises a fresh issue of equity shares aggregating up to Rs 210 crore and OFS of 43 lakh equity shares by promoter entity Grandhi Bharata Mallika Ratna Kumari (HUF), according to the draft red herring prospectus (DRHP).
Proceeds of the fresh issue will be utilised to finance the establishment of eight new showrooms, costing Rs 12 crore, and the purchase of inventory worth Rs 160 crore over FY23 and FY24, besides general corporate purposes.
Visakhapatnam-headquartered Vaibhav Jewellers offers a wide range of products in gold, diamonds, gems, platinum and silver jewellery or articles. Its sub-brand Visesha caters to a premium segment of gold and diamond jewellery.
Shares of both companies will be listed on the BSE and NSE.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.